Innovative 3D culture-based drug sensitivity test shows promise for malignant bone tumors
A novel 3D culture-based drug sensitivity test (DST) shows significant promise in guiding personalized treatment for surgically resected malignant bone tumors, particularly osteosarcoma, according to a study.
The study found that this new method effectively identified potentially effective drugs for these tumors, even in cases with specific genetic mutations. Additionally, the DST approach demonstrated consistency in drug sensitivity results between different types of samples, showcasing its robustness.
The evaluation was conducted using 2 osteosarcoma cell line (KCS8 or KCS9)-derived xenograft (CDX) models.
Among the noteworthy findings, researchers discovered that out of 60 drugs examined, 23 (in the case of KCS8) and 39 (in KCS9) were deemed likely effective in osteosarcoma cells derived from a cell line before xenografting. The number of selected effective drugs in cells derived from a CDX tumor was slightly lower, with 19 and 26 for KCS8 and KCS9 respectively. The study revealed a significant correlation in drug sensitivities between both types of samples.
The research demonstrated that the drug sensitivity of a CDX tumor remained largely unaltered even after the removal of non-tumorous components from the sample, emphasizing the robustness and reliability of this testing method.
Reference
Goto H, Ohtsu T, Ito M, et al. A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors. Hum Cell. 2023;doi: 10.1007/s13577-023-00982-8. Epub ahead of print. PMID: 37707773.
